

Increased $\Delta 133p53$ mRNA in lung carcinoma corresponds with reduction of *p21* expression

AIKATERINI FRAGOU¹, GEORGIOS TZIMAGIORGIS¹,
CHRISTOS KARAGEORGOPOULOS¹, NIKOLAOS BARBETAKIS², AXILLEAS LAZOPOULOS²,
MARIA PAPAIOANNOU¹, COSTAS HAITOGLOU¹ and SOFIA KOUIDOU¹

¹Laboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124; ²Department of Thoracic Surgery, Theagenion Anticancer Hospital, Thessaloniki 54007, Greece

Received March 27, 2016; Accepted October 20, 2016

DOI: 10.3892/mmr.2017.6162

Abstract. Modification of *p53* expression levels and its principle apoptosis and cell cycle regulatory partners, mouse double minute 2 homolog (*MDM-2*) and *p21*, has been previously reported in various types of cancer. In the current study, the expression of $\Delta 133p53$ isoforms was investigated in lung carcinomas with respect to the expression of the aforementioned genes. The expression of *p53* full-length transcript and $\Delta 133p53$ isoforms α , β and γ transcripts, *MDM-2* and *p21* transcripts were determined by reverse transcription-quantitative polymerase chain reaction, in total RNA isolated from 17 lung carcinoma specimens and 17 corresponding adjacent non-cancerous tissues. RNA expression analysis was performed according to the Pfaffl equation and Rest tool using β -actin as a reference gene. Detection of the above proteins was additionally performed by western blotting. Significant overexpression of the $\Delta 133p53$ mRNAs was observed in cancerous as compared with adjacent non-cancerous tissues (3.94-fold), whereas full-length *p53* and *MDM-2* expression exhibited a smaller, however significant, increase. The expression of the *p21* transcript was significantly reduced in cancerous specimens. $\Delta 133p53$ and *p21* expression levels varied in parallel, however were not significantly correlated. *p53* full-length protein expression observed by western blot analysis strongly varied from the $\Delta 133p53$ isoforms, however *MDM-2* protein isoforms were not detectable and *p21* protein was more abundant in non-cancerous tissues. In conclusion, $\Delta 133p53$ mRNA levels is suggested as a potentially useful marker of malignancy in lung cancer. The absence of $\Delta 133p53$ protein in lung carcinomas, which overexpress $\Delta 133p53$ transcripts, may

indicate the role of the latter in post-transcriptional regulation through RNA interference in the cell cycle and apoptosis.

Introduction

p53 is a key regulator of growth arrest, senescence and apoptosis in response to a wide array of cell damage events (1). Rapid induction of high *p53* protein levels under different stress conditions prevents inappropriate propagation of cells carrying potentially mutagenic, damaged DNA (2). The central role of *p53* in the cell stress response lends significance to the existence of at least nine different *p53* isoforms arising from differential splicing and promoter usage (3). These isoforms are expressed in normal tissue in a tissue-dependent manner and their differentiated expression in human cancer suggests that they may be involved in tumor development or progression (4).

The $\Delta 133p53$ isoform(s) of tumor suppressor *p53* are transactivated by *p53* in response to stress (5). The $\Delta 133p53$ isoforms are lacking the first 133 amino acids and the expression of their mRNA is derived from an alternative internal promoter located in intron 4 of *p53*. Lack of the *p53* N-terminus is responsible for a dominant negative inhibition of normal apoptotic function of the *p53* protein. Therefore, the excessive expression of these isoforms may serve a critical role and interfere with normal *p53* function. The $\Delta 133p53$ isoforms are implicated in controlling cellular senescence and elevated levels of these isoforms have been observed in a variety of tumors. Elevated expression of $\Delta 133p53$ isoform(s) has been observed in breast cancer and in renal cell carcinoma, whereas in colon cancer, progression from colon adenoma to carcinoma is accompanied by an increase of $\Delta 133p53$ mRNA (6). In addition to its multiple functions, *p53* has been additionally identified to suppress metastasis and inhibit angiogenesis, a process strongly contributing to tumor development (7). Bernard *et al* (8) established that angiogenesis and growth of glioblastoma U87 tumors are inhibited upon depletion of the $\Delta 133p53\alpha$ isoform and that this isoform induces pro-angiogenic gene expression and represses anti-angiogenic gene expression. Furthermore, previous analysis of germline *p53* mutations in breast cancer by Kouidou *et al* (9) demonstrated that the Li-Fraumeni and Li-Fraumeni-like syndromes are

Correspondence to: Professor Sofia Kouidou, Laboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
E-mail: kouidou@auth.gr

Key words: $\Delta 133p53$ isoforms, *MDM-2*, *p21*, lung cancer

closely associated with the loss of the initiation codon 133 of the $\Delta 133p53$ isoforms, thus indicating that these isoforms serve a regulatory role and are associated with carcinogenesis.

In the current study, the expression levels of transcripts leading to the expression of $\Delta 133p53$ isoforms were identified in lung cancer. In addition, due to the fact that p53 serves a pivotal role within the cell and is subjected to a tight and orchestrated control, creating a network of positive and negative regulations (10), the association of $\Delta 133p53$ mRNA expression with respect to that of mouse double minute 2 homolog (*MDM-2*) and *p21*, two of its principle regulatory partners, was investigated. MDM-2 has been identified as the principal cellular antagonist of p53 by limiting p53 tumor suppressor activities (11). Through binding to the N-terminal transactivation domain, MDM-2 is involved in p53 degradation in the cytoplasm (12), thus suppressing its activity. MDM-2, an E3 ubiquitin ligase of the RING-finger family, is involved in p53 regulation. The RING domain permits the direct binding of ubiquitin enzymes resulting in mono- or poly-ubiquitination of p53 (13). p21 is a notable effector of p53 and is a general inhibitor of cyclin-dependent kinases, functioning to negatively regulate the cell cycle. The expression of *p21* is upregulated by the p53 response to DNA damage, leading to cell-cycle arrest at the G₁ checkpoint (14). Similar to other types of human cancer, approximately 50% of lung cancer types exhibit mutations in p53 (15), however the relative expression of the $\Delta 133p53$ isoforms remains to be fully elucidated in association with this disease.

Materials and methods

Tissue specimens. Surgical specimens, primary tumor samples and corresponding non-malignant tissues, were obtained from 17 patients admitted to Theageneion Anticancer Hospital (Thessaloniki, Greece) immediately after the excision of non-small cell lung carcinoma during resection surgery (Table I). Thirteen of the patients were male (mean age, 61.27 years) and three female (mean age, 58 years). Macroscopically non-cancerous lung tissue was obtained from a distal site at the excision limit from the same individual. Samples were immediately snap-frozen and stored in liquid nitrogen prior to long-term storage at -80°C. This study was approved by the ethics committee of Theageneion Anticancer Hospital. The human lung adenocarcinoma epithelial cell line (A549) and the human lung fibroblast cell line (MRC-5) were also analysed. The cell lines were kindly provided by Dr George Geromichalos (Theageneion Anticancer Hospital).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays for detection of p53, full-length and $\Delta 133p53$, MDM-2 and p21 mRNA and statistical analysis of the results. Total RNA was extracted with the SV Total RNA Isolation System (Promega Corporation, Madison, WI, USA) treated with DNase (Promega Corporation), both integrity and purity were confirmed via spectrophotometry and agarose gel electrophoresis. cDNA was synthesized using oligodT and Superscript II Reverse Transcriptase (Promega Corporation). cDNA (2 μ g) were then used for the PCR reaction. For quantification of p53, full-length and $\Delta 133p53$ isoforms, *MDM-2* and *p21* transcripts, RT-qPCR was performed using 125 ng RNA

Table I. Epidemiological characteristics of samples used in the experiments of the current study, documentation of the histopathology analysis of each patient, the age, gender and the smoking habits (packs per years) are presented.

Sample no.	Histopathology	Age	Gender	Smoking (packs/year)
1	Squamous	44	M	60
6	NSCLC	N/A	F	70
9	NSCLC	N/A	M	Non-smoker
11	NSCLC	73	M	55
12	Adenocarcinoma	42	M	63
13	Squamous	N/A	M	40
20	Adenocarcinoma	47	M	60
27	NSCLC	N/A	N/A	N/A
38	Adenocarcinoma	75	M	Non-smoker
39	NSCLC	58	M	30
40	NSCLC	66	F	Non-smoker
41	Adenocarcinoma	67	M	150
42	NSCLC	65	M	140
43	NSCLC	66	M	200
44	NSCLC	60	M	60
45	NSCLC	77	M	60
46	Adenocarcinoma	48	F	70

N/A, not available; NSCLC, non-small cell lung cancer.

with 2X Power SYBR-Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's instructions and performed on Applied Biosystems StepOnePlus Real Time PCR System (Thermo Fisher Scientific, Inc.). The cycling conditions were as follows: 95°C for 10 min, then 40 cycles of 95°C for 30 sec, 56°C for 30 sec, 72°C for 30 sec, followed by melting curve analysis up to 95°C. The primer sequences used were as follows: Full-length p53, P53EX3S 5'-TCCATG GGACTGACTTTCTGC-3' and P53EX4AS 5'-CTGGCA TTCTGGGAGCTTCA-3'; $\Delta 133p53$ isoforms, P534b 5'-TAG ACGCCAACTCTCTCTAG-3' and P53RE5 5'-TTGGCA AAACATCTTGTGAGGGC-3'; *MDM-2*, MDM2S 5'-CTG AAATTTCCCTAGCTGAC-3' and MDM2AS 5'-TTCAGG AAGCCAATTCTCAC-3'; *p21*, P21S 5'-TGGACCTGT CACTGTCTTGT-3' and P21AS 5'-TCCTGTGGGCGG ATTAG-3' and β -actin: B-ACTINS 5'-CGTCTTCCCCCTC CATCGTG-3' and B-ACTINAS 5'-CTTCTGACCCATGCC CACCA-3'. The primers were designed in our laboratory with the exception of primers P21S and P21AS, which were designed as described previously (16). All primers were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.) The molecular weight of PCR products was verified by agarose gel electrophoresis.

In order to quantify and compare the amplification products, Cq data corresponding to the target genes were normalised relative to those of an internal housekeeping gene, β -actin. Each data point was obtained twice. Quantitative values were estimated from the quantification PCR cycle




Figure 1. mRNA expression of *p53*, full-length and $\Delta 133p53$, *MDM-2* and *p21* relative to β -actin (reference gene) for each individual lung carcinoma and corresponding adjacent non-cancerous specimens. The C_q values were analyzed by the $2^{-\Delta\Delta C_q}$ method using Pfaffl analysis. ---, 95% confidence interval limit. MDM-2, mouse double minute 2 homolog.

number (C_q) at which the increase in signal associated with an exponential growth for PCR product starts to be detected. The relative mRNA levels in each sample were normalised to its β -actin mRNA content. The relative expression level of the target gene was analysed by the $2^{-\Delta\Delta C_q}$ method (17). For each sample, the difference in C_q values for the gene of interest and the endogenous control was calculated (ΔC_q) (17). In addition, the REST[®] tool (relative expression software, version 2009; Qiagen GmbH, Hilden, Germany) which compares two groups (cancerous vs. non-cancerous tissue) with up to 16 data points in each group for reference, and up to four target genes (18).

Protein extraction. The surgical specimens were homogenized into a fine powder using a mortar and pestle in liquid nitrogen and maintained at -80°C . For the total protein extraction 100 mg of homogenized tissue was resuspended in 300 μl lysis buffer (50 mM Tris/HCl pH 8, 150 mM NaCl, 0.02% (w/v) sodium azide, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 0.4 mM EDTA, 10 mM NaF, 0.75 mM PMSF, 1% v/v protease inhibitor cocktail EDTA-free). The cells were then lysed by performing 5 freeze-thaw cycles in liquid nitrogen and 37°C water bath. Subsequent to incubation for 4.5 h at 4°C under rotation, the suspension was centrifuged at $15,000 \times g$ for 25 min at 4°C . The supernatant was maintained at -80°C until later use.

Semi-dry western blotting analysis. Following electrophoresis, the proteins were transferred onto nitrocellulose membranes (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) in the presence of blotting buffer (12.5 mM H_3BO_3 , 12.5 mM Tris/HCl pH 8.5, 0.02% w/v SDS) by applying 64 mA for 15 min. The membranes were blocked for 1 h in 5% non-fat dry milk in phosphate-buffered saline with 0.1% Tween-20 at room temperature. Incubation with the primary antibodies was performed overnight at 4°C , followed by incubation with the secondary antibody conjugated to alkaline phosphatase for 1 h at room temperature. The signals in the immunoblots were

detected indirectly by staining with NBT/BCIP (Biotium, Fremont, CA, USA). The mouse anti-p53 antibody (Pab 240; sc-99) raised against amino acids 156-214 of p53 of human origin and the rabbit anti-p21 (C-19, sc-397) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and used at a working dilution of 1:500. The rabbit anti-MDM-2 antibody (S166; AP1253e) was purchased from Abgent (San Diego, CA, USA) and used at a 1:1,000 working dilution. The secondary anti-rabbit (7054F) and anti-mouse (7056) IgG-alkaline phosphatase antibodies (1:4,000 working dilution) were purchased from Cell Signalling Technology, Inc. (Danvers, MA, USA). The image capturing was performed with the Molecular Imager[®] Gel Doc[™] XR+ System with Image Lab[™] Software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Due to the fact that staining of the β -actin protein was inadequate, Coomassie Blue Staining was used as a loading control for the western blot analysis (19). Variation of β -actin steady-state expression levels in the lung may be responsible for the limited use of this protein as a control (19).

Results

Expression of *p53*, full-length and $\Delta 133p53$, *MDM-2* and *p21* transcripts, using RT-qPCR. Using specific primers and RT-qPCR, the full-length *p53* transcript, $\Delta 133p53$ (for $\Delta 133p53\alpha$, $\Delta 133p53\beta$ and $\Delta 133p53\gamma$ a common set of primers was used), in addition to *MDM-2* and *p21* transcripts were amplified. In each case, the data were verified by replicate tests. The normalized average for each sample relative to the actin control was calculated using the Pfaffl equation (Fig. 1). Fig. 1 illustrates the wide variation of the relative expression of *p53*, full length and $\Delta 133p53$, *MDM-2* and *p21* transcripts in the majority of samples. However, the most considerable variation was observed in $\Delta 133p53$ transcript expression (3.94-fold increase), which according to the Pfaffl criteria (>1.5) was statistically significant.

Table II. Expression of full-length *p53*, $\Delta 133p53$, *MDM-2* and *p21* transcripts in the different tissues and cell lines.

A, Cancerous tissues relative to non-cancerous tissues for the carcinoma specimens

Gene	Type	Reaction efficiency	Expression	P(H1)	Result
<i>β-actin</i>	REF	1.0	0.872	0.845	
<i>p53</i>	TRG	1.0	1.379	0.787	
$\Delta 133p53$	TRG	1.0	3.436	0.012	Up
<i>MDM-2</i>	TRG	1.0	1.232	0.756	
<i>p21</i>	TRG	1.0	0.509	0.470	

B, The adenocarcinoma epithelial cell line A549 and the human lung fibroblast cell line MRC-5

Gene	Type	Reaction efficiency	Expression	P(H1)	Result
<i>β-actin</i>	REF	1.0	0.521	0.509	
<i>p53</i>	TRG	1.0	2.346	0.000	Up
$\Delta 133p53$	TRG	1.0	5.169	0.000	Up
<i>MDM-2</i>	TRG	1.0	0.570	0.509	
<i>p21</i>	TRG	1.0	0.287	0.000	Down

Values were normalized relative to the *β -actin* using the Rest statistical analytical tool. REF, reference gene; TRG, target gene; *MDM-2*, mouse double minute 2 homolog.

Table III. Comparison of $\Delta 133p53$ expression vs. *MDM-2* and *p21* in cancerous vs. non-cancerous tissue using the Rest statistical analytical tool.

Gene	Type	Reaction Efficiency	Expression	P(H1)
$\Delta 133p53$	REF	1.0	1.000	
<i>MDM-2</i>	TRG	1.0	0.384	0.208
<i>p21</i>	TRG	1.0	0.157	0.052

MDM-2, mouse double minute 2 homolog; REF, reference gene; TRG, target gene.

Analysis of the relative expression of *p53*, full-length and $\Delta 133p53$, *MDM-2* and *p21* transcripts in cancerous vs. non-cancerous tissue. In order to quantify the relative alterations in expression of the genes studied, REST[®] analysis was used. The results presented in Table IIA demonstrate significant overexpression of the $\Delta 133p53$ transcripts in cancerous vs. non-cancerous tissue, in addition to a smaller overexpression of *p53* and *MDM-2* in the above tissues. On the contrary, *p21* was observed to undergo a small reduction of expression in the cancerous tissue relative to the non-cancerous tissues. The same conclusions were drawn for the relative expression

of *p53*, full-length, $\Delta 133p53$ and the *MDM-2* transcripts in the cancerous A549 cell line compared with the non-cancerous MRC-5 cell line (Table IIB). *p21* was significantly under-expressed in the cancerous A549 cell line. Thus, $\Delta 133p53$ appears to be the most overexpressed of the above transcripts in the cancerous tissues.

Comparison of *MDM-2* and *p21* expression relative to *p53* full-length and to $\Delta 133p53$. In order to acquire a more sensitive marker indicative of the alterations associated with cancer, the relative expression differences of *MDM-2* and *p21* vs. $\Delta 133p53$ were investigated in cancerous tissues compared with non-cancerous tissues. The results presented in Table III indicate that the relative expression of *p21* vs. $\Delta 133p53$ exhibited a marginally stronger, however not significant, variation ($P=0.052$). Furthermore, investigation of the *MDM-2*, *p21* and $\Delta 133p53$ expression vs. full-length *p53* expression in cancerous and non-cancerous tissue (results not shown) identified smaller differences of the above transcripts with respect to both *MDM-2* and *p21* expression.

Comparison of *p53*, full-length and $\Delta 133p53$, *MDM-2* and *p21* expression relative to smoking. Due to the fact that cigarette consumption (packs/year) may be another parameter affecting the expression of these genes, the transcript differences with respect to smoking were additionally measured. Of the patients, three were heavy smokers (140-200 packs/year), while, three other patients had never smoked and the remaining 10 patients were intermediate smokers who consumed a smaller number of packs/year (40-70 packs/year). The analysis conducted for cancerous vs. non-cancerous tissues relative to smoking (Fig. 2) indicated that there were several consistent differences in gene expression. One difference was the absence of $\Delta 133p53$ overexpression in cancerous vs. non-cancerous tissue among non-smokers (Fig. 2A), detectable overexpression among intermediate smokers (Fig. 2B) and strong overexpression in heavy smokers (Fig. 2C). On the contrary, *p53* and *MDM-2* differences were similar in all groups in cancerous and non-cancerous tissues and thus not differentiated with respect to smoking. *p21* expression did not vary considerably between cancerous and non-cancerous tissue with respect to smoking. In the small number of these cases, the above results were consistent although not statistically significant.

Western blotting analysis of *p53*, full-length and $\Delta 133p53$ isoforms, *MDM-2* and *p21*. Comparison to mRNA expression. *p53* protein expression and the presence of its different isoforms, in addition to *MDM-2* and *p21* proteins were then analyzed in representative samples with varying levels of $\Delta 133p53$ transcript expression: High (samples 13 and 42); intermediate level (sample 9); and low (sample 38). For this purpose the Pab-240 anti-*p53* antibody was used, specific for the common exons 5-6 in the DNA binding region of *p53*, amino acids 156-214, which does not differentiate between α , β and γ variants. Using this antibody, almost all *p53* isoforms were detected at differing in addition to the $\Delta 40p53$ β and γ isoforms (42 kDa) formed major intensity products (Fig. 3). Detectable truncated isoform $\Delta 133p53\alpha$ (35 kDa) was observed in sample 13C and $\Delta 133p53\beta$ and γ (29 kDa) were weakly detected in sample 9NC. The C-terminus truncated




Figure 2. Expression of *p53*, full-length and $\Delta 133p53$, *MDM-2* and *p21* transcripts in cancerous vs. non-cancerous tissue in (A) non-smokers (B) intermediate smokers (40-70 packs/year) and (C) heavy smokers (140-200 packs/year) using the Rest statistical analytical tool. —, difference limit for the relative expression levels. *MDM-2*, mouse double minute 2 homolog.

p53 β and *p53* γ were detectable in almost all samples. The relative abundance of the smaller isoforms could not be correlated with the corresponding transcript abundance (Fig. 1). Thus, in samples 9 and 42, overexpressing the $\Delta 133$ transcripts, corresponding isoforms were not observed.

In the majority of cases, *p21* protein was more abundant in adjacent normal lung tissue (Fig. 3B) compared with cancerous samples, and in accordance with the corresponding RT-qPCR results. Western blotting analysis did not provide conclusive evidence for *MDM-2* protein isoforms (results not shown).

Discussion

Expression of full-length *p53* mRNA, its isoforms and their principle co-regulators, apoptosis effector *MDM-2* and cell cycle regulator *p21*, serve a critical role in the process of lung carcinogenesis. In the current study, it was reported, to the




Figure 3. Western blot analysis of (A) *p53* and (B) *p21* proteins in C and NC specimens. The samples represent varying levels of $\Delta 133p53$ transcript expression: High (samples 13 and 42); low (sample 38) and intermediate (sample 9). Molecular weight markers are displayed on the left, whereas the predicted isoforms and corresponding molecular weights (kDa) are displayed on the right. Positive samples are indicated with arrows corresponding to their molecular weights in A. *p53* was present at 53 kDa and its isoforms with variable molecular weights, and *p21* is presented in B at 21 kDa. C, carcinoma; NC, adjacent normal lung specimens.

best of our knowledge, for the first time, that in addition to the parallel *MDM-2* and *p53* expression variation in cancerous compared with adjacent non-cancerous lung tissue, $\Delta 133p53$ isoforms are significantly overexpressed in cancerous lung tissue. On the contrary, *p21* is significantly under-expressed in cancerous lung tissue samples. The observed inverse association of $\Delta 133p53$ isoforms and *p21* expression was not statistically significant.

Although the $\Delta 133p53/p53$ mRNA was most abundant in the cancerous samples, the $\Delta 133p53$ protein isoforms were not detectable in samples overexpressing the mRNA of these isoforms. By contrast, *p21* protein expression was correlated with *p21* mRNA expression, in the cancerous and non-cancerous lung tissues used in the present study. The differences observed by western blotting analysis demonstrated inconsistencies between mRNA and protein production, which are observed primarily in cancerous tissues and also verified in previous studies in other types of cancer (20,21). It is suggested that the overexpression of $\Delta 133p53$ isoforms may exert its effect through *p53* transcript interference. Transcript interference appears to be a common mechanism by which mRNAs lacking their 5' sequences act (22,23). It has been previously reported that $\Delta 133p53$ isoforms differentially modulate *p53* target gene expression to antagonize *p53* apoptotic activity at the physiological level in zebra fish and that the knockdown of $\Delta 133p53$ enhances *p53*-mediated apoptosis under stress conditions (24). A recent study did however demonstrate that the $\Delta 133p53$ isoforms are also negatively involved in DNA damage repair and inhibition of cell senescence (25). The observations of the current study demonstrate that the $\Delta 133p53$ transcript overexpression may additionally have a negative effect on DNA damage repair in lung cancer where mutations are very frequent. This condition paralleled by the *p21* transcript reduction is suggested to strongly affect carcinogenesis in the lung.

Numerous studies have identified the impact of different isoforms on cancer biology (26-28). Alternatively spliced tissue factor (TF) isoform expression is differentially modulated on a post-transcriptional level via regulatory factors including serine/arginine-rich (SR) proteins, SR protein kinases and microRNAs. These isoforms participate in a variety of

physiological and pathophysiological functions, including thrombogenicity, angiogenesis, cell signalling, tumor cell proliferation and metastasis (26). Specifically, Goldin-Lang *et al* (27) observed that upregulation of human full length tissue factor and, particularly, an alternatively spliced human tissue factor in pulmonary adenomatosis, suggested raised risk of thrombosis and tumor progression, thereby indicating poor prognosis in these patients. In addition, in A549 human lung cancer cells, modulation of TF isoform expression, which is controlled by alternative splicing, modulates the pro-angiogenic potential of these cells under hypoxic conditions (28).

In conclusion, the present study verifies the potential value of $\Delta 133p53$ isoform(s) overexpression as a marker for lung malignancy, and contributes to our understanding of its role in cell cycle regulation. This information is vital for elucidating lung carcinogenesis and investigating its drug sensitivity.

Acknowledgements

The current study was supported by the National Strategic Reference Framework Central Actions for PhD studies (grant no. 84643; 2007-2013) and the Programme for Development, European Social Fund, Education and Lifelong Learning, Heraclitus II.

References

- Herce DH, Deng W, Helma J, Leonhardt H and Cardoso MC: Visualization and targeted disruption of protein interactions in living cells. *Nat Commun* 4: 2660, 2013.
- Vousden KH and Lu X: Live or let die: The cell's response to p53. *Nat Rev Cancer* 2: 594-604, 2002.
- Davidson RW, Kari C, Ren Q, Daroczi B, Dicker PA and Rodeck U: Differential regulation of p53 function by the N-terminal $\Delta Np53$ and $\Delta 113p53$ isoforms in zebrafish embryos. *BMC Dev Biol* 10: 102, 2010.
- Song W, Huo SW, Lü JJ, Liu Z, Fang XL, Jin XB and Yuan MZ: Expression of p53 isoforms in renal cell carcinoma. *Clin Med J (Engl)* 122: 921-926, 2009.
- Khouri MP and Bourdon C: p53 Isoforms. An intracellular microprocessor? *Genes Cancer* 2: 453-465, 2011.
- Wel J, Zaika E and Zaika A: p53 Family: Role of protein isoforms in human cancer. *J Nucleic Acids* 2012: 687359, 2012.
- Teodoro JG, Evans SK and Green MR: Inhibition of tumour angiogenesis by p53: A new role for the guardian of the genome. *J Mol Med (Berl)* 85: 1175-1186, 2007.
- Bernard H, Garmy-Susini B, Ainaoui N, Van Den Berghe L, Peurichard A, Javerzat S, Bikfalvi A, Lane DP, Bourdon JC and Prats AC: The p53 isoform, $\Delta 133p53\alpha$, stimulates angiogenesis and tumour progression. *Oncogene* 32: 2150-2160, 2013.
- Kouidou S, Malousi A, Kyventidis A, Fragou A and Maglaveras N: G:C>A:T mutations and potential epigenetic regulation of p53 in breast cancer. *Breast Cancer Res Treat* 106: 351-360, 2007.
- Pekova S, Cmejla R, Smolej L, Kozak T, Spacek M and Prucha M: Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. *Leuk Res* 32: 395-400, 2008.
- Ute M and Petrenko O: The MDM2-p53 interaction. *Mol Cancer Res* 1: 1001-1008, 2003.
- Freedman DA and Lavine AJ: Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. *Mol Cell Biol* 18: 7288-7293, 1998.
- Itahana k, Mao H, Jin A, Itahana Y, Clegg H, Lindström MS, Bhat KP, Godfrey VL, Evan GI and Zhang Y: Targeted inactivation of Mdm2 Ring finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. *Cancer Cell* 12: 355-366, 2007.
- Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. *Nature* 366: 701-704, 1993.
- Guimaraes DP and Hainaut P: TP53: A key gene in human cancer. *Biochimie* 84: 83-93, 2002.
- Sun P, Qiu Y, Zhang Z, Wan J, Wang T, Jin X, Lan Q, Rothman N and Xia ZL: Association of genetic polymorphisms, mRNA expression of p53 and p21 with chronic benzene poisoning in a Chinese occupational population. *Cancer Epidemiol Biomarkers Prev* 18: 1821-1828, 2009.
- Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 3: 1101-1108, 2008.
- Pfaffl MW, Graham WH and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucl Acids Res* 30: e36, 2002.
- Welinder C and Ekblad L: Coomassie staining as loading control in Western blot analysis. *J Proteome Res* 10: 1416-1419, 2011.
- Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Schouli J, Braicu EI, Mahner S, *et al*: $\Delta 133p53$ is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. *Br J Cancer* 105: 1593-709, 2011.
- Moore CH, Jordan BL, Bray ES, Baker L, Quinlan RP, Purdie CA, Thompson AM, Bourdon JC and Fuller-Pace FV: The RNA helicase p68 modulates expression and function of the $\Delta 133$ isoform(s) of p53, and is inversely associated with $\Delta 133p53$ expression in breast cancer. *Oncogene* 29: 6475-6484, 2010.
- Dewing AS, Rueli RH, Robles MJ, Nguyen-Wu ED, Zeyda T, Berry MJ and Bellinger FP: Expression and regulation of mouse selenoprotein P transcript variants differing in non-coding RNA. *RNA Biol* 9: 1361-1369, 2012.
- Keene JD: RNA regulons: Coordination of post-transcriptional events. *Nat Rev Gene* 8: 533-543, 2007.
- Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP and Peng J: p53 isoform $\Delta 113p53$ is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. *Genes Dev* 23: 278-290, 2009.
- Gong L, Gong H, Pan X, Chang C, Ou Z, Ye S, Yin L, Yang L, Tao T, Zhang Z, *et al*: p53 isoform $\Delta 113p53/\Delta 133p53$ promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. *Cell Res* 25: 351-369, 2015.
- Leppert U and Eisenreich A: The role of tissue factor isoforms in cancer biology. *Int J Cancer* 137: 497-503, 2015.
- Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP and Rauch U: Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumour metastasis. *Oncol Rep* 20: 123-128, 2008.
- Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, Schultheiss HP, Pries A and Rauch U: Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. *Oncol Rep* 30: 462-470, 2013.